San Francisco and its hotel industry are partnering to beef up security around this week's 43rd annual J.P. Morgan Healthcare ...

That brand is more than just a logo - it’s your company’s reputation ... including a recent campaign from Gilead Science. Meanwhile, Kantar recorded a 208% jump in spending on podcast pharma ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

The most recent trading session ended with Gilead Sciences (GILD) standing at $93.85, reflecting a -1.57% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0 ...

Gilead Sciences GILD +2.54% Get Free Report has outperformed the market over the past 20 years by 4.74% on an annualized ...

The latest trading session saw Gilead Sciences (GILD) ending at $92.96, denoting a +1.22% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of ...

Shares of Gilead Sciences Inc. GILD rallied 1.52% to $92.38 Wednesday, on what proved to be an all-around great trading ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant have gained 26.8% in the past six months against the industry’s ...

Gilead Sciences Inc (GILD) stock saw a decline, ending the day at $92.92 which represents a decrease of $-0.12 or -0.13% from the prior close of $93.04. The stock opened at $93.03 and touched a low of ...